VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders

Henderson, Nevada, August 26, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

Key Highlights:

• Sepsis & NETosis Validation: Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic shock patients. $7.3 million government-backed DETECSEPS program in France due to start recruitment in September 2026.
• Demonstrates Clinical Utility of Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow, thereby potentially greatly expanding the addressable market and utility.
• European Lung Cancer Reimbursement: Plans formal conditional reimbursement submission in France by the end of 2026 to enable routine clinical use.
• First Half Revenue Growth: Reported $1.4M of revenue in the first half of 2026, representing a 112% increase year-over-year.
• Feline Lymphoma Manuscript Submission: Submitted for publication the clinical manuscript for the Nu.Q^® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication.
• Global Licensing Momentum: Confirms active discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies, including for technical evaluations.
• Newly Announced Collaboration: Successfully transferred Volition Nu.Q^® NETs assay onto Sysmex Corporation’s platform, in preparation for anticipated broader agreement. Sysmex Corporation is a multi-billion dollar market capitalization company listed on the Tokyo Stock Exchange.
• Capture-Seq™ Platform: Peer-reviewed paper published: validation cohort detected over 95% of Stage I and II cancers. Underscores a $23 billion annualized opportunity in cancer detection.

Sepsis & NETosis Validation

We were honored that Nu.Q^® NETs H3.1 featured in an editorial¹ in Critical Care Medicine, a prominent journal for Critical Care doctors around the world and were excited that the findings of another large-scale independent clinical study were peer-reviewed and published² in that journal. These findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition’s $2.8 billion addressable market³.

The inclusion of our Nu.Q^® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France remains on track to start in the third quarter of 2026. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis.

In the first half of 2026, we also reported two new, potentially large, clinical use cases for our Nu.Q^® NETs assay beyond sepsis. In conjunction with the Mayo Clinic⁴, we demonstrated Nu.Q^® NETs’ potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care⁴. We plan to further validate with Mayo the use of Nu.Q^® NETs in trauma patients.

We have also demonstrated the potential use of Nu.Q^® NETs for patient management of a chronic disease, Hidradenitis Suppurativa⁵, which affects about 1% of the world’s population⁶.

NETosis-related diseases beyond sepsis provide an additional $1 billion Total Addressable Market on an annualized basis³.

Breakthrough Finger-Prick Detection of Nucleosomes

Excitingly for Nu.Q^® NETs we have also made excellent progress in the development and evaluation of our lateral flow prototype assay. This has the potential to strengthen our product portfolio. In April, we reported the technical breakthrough of being able to detect nucleosomes in capillary blood (or finger prick blood) and more recently in August, we reported we have demonstrated correlation of the lateral flow prototype assay and our established CE marked automated Nu.Q^® NETs assay in samples of critically ill, confirmed sepsis patients in the Intensive Care Unit.

The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device aims to enable quicker clinical decision making and consequently better patient outcomes.

This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing.

With recent estimates indicating approximately 166 million cases of sepsis worldwide, the addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%⁷ of total global deaths, with the highest burden of mortality in lower-middle-income countries.

We are now actively targeting NGO partnerships and strategic collaborations with companies operating in low income countries to accelerate the commercialization and market penetration of our breakthrough Lateral Flow Assay.

Nu.Q^® Lung Cancer Reimbursement Submission

Lung Cancer remains the major cause of cancer-related mortality worldwide.

We believe that Nu.Q^® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.

Research conducted by our long-term collaborators in Taiwan and Lyon demonstrates that our Nu.Q^® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey^8-13.

This evidence provides the basis of our European lung cancer reimbursement submission supported by our long-term collaborators at the Hospices Civils de Lyon, one of Europe’s leading cancer centers.

Reimbursement is the next step on the path to the first use of Nu.Q^® in clinical practice, an exciting prospect which is core to Volition’s mission, using our tests to help save lives. This quarter we participated in our first pre-submission meeting with the authorities and anticipate a follow-up meeting and ultimately a submission in 2026.

Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q^® in the human cancer field and, assuming achievement, we anticipate the introduction into routine clinical use in France and will then set our sights on rolling-out to other countries.

Capture-Seq™ Breakthrough in Cancer Detection.

We were delighted  thar our manuscript entitled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy” has been peer-reviewed and published¹⁴. This, our first peer-reviewed paper for Capture-Seq™, showcasing both a new method and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.

We also announced over 95% sensitivity for stage I & II cancers with 95% specificity in a blinded validation cohort¹⁵. For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.

We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of our Capture-Seq™ technology and undertake technical evaluations with potential licensors.  We believe that this technology could, with further development, become very widely used and are actively advancing structured discussions with potential commercial partners to accelerate the integration and launch of this technology as soon as possible.

We believe MCED represents a significant commercial opportunity with Total Addressable Markets on an annualized basis of approximately $23 billion  and a potential additional $13 billion should it also prove useful in the detection of Minimal Residual Disease³.

Companion Animal Health: Nu.Q^® Vet Feline Milestone

We announced the submission of a clinical manuscript reporting the high accuracy of our Nu.Q^® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species¹⁷. At 97% specificity the assay detected 86% of feline lymphomas¹⁶. This breakthrough marks the development of what we expect to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.

This represents a tremendous commercial opportunity for Volition:

• the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.
• we will also generate ongoing revenue in this large and growing market where our technology meets an unmet need.

The Nu.Q^® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space³.

Our Goal and Vision

We have developed a truly remarkable, versatile platform and have further strengthened our Intellectual Property portfolio as we continue our licensing discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies. Our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.

We are delighted to have grown the commercial interest in the first half with an increase in discussions, including technical evaluations. Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.

Our vision is for our technologies to be incorporated into tests that will be used first by millions,  and ultimately, hundreds of millions of people and animals a year, with our platform licensed to a range of large diagnostic and liquid biopsy companies (and governments) worldwide. Combining our groundbreaking technology with their installed base of laboratories, analyzer machines and sales forces around the world will achieve the optimal outcome for us – large companies have the resources to realize the opportunities better than Volition.

The Total Addressable Markets³ (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities, not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.

Summary of Addressable Markets (TAM)³

1. Crowley H., Rachoin J-S., Crit Care Medicine 2026 https://doi.org/10.1097/ccm.0000000000007321
2. Neumann C. et al., H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial Crit Care Med, 2026 DOI: 10.1097/CCM.0000000000007270
3. Data on File: Volition TAM Model
4. Navarro, Sergio M. et al., Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. Shock, 2026.DOI: 10.1097/SHK.0000000000002807
5. Styliani Theohar et al., Plasma H3.1-Nucleosomes to Classify Severity and Surrogate Response to Treatment in Hidradenitis Suppurativa : A Cohort Study. medRxiv https://doi.org/10.64898/2026.01.13.26343988
6. Bouazzi D, Nielsen SM, Hagan PG, et al. JAMA Dermatol.https://doi.org/10.1001/jamadermatol.2025.2373
7. Gray, Authia P et al.,  Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0
8. Kotronoulas A,et al., Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence. PrePrint
9. Piecyk M. et al., Prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer. PrePrint
10. Grolleau E, et al., Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255
11. Couraud S., et al., Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. Poster ELCC 2024
12. Piecyk M. et al., “H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline” Poster 395 ELCC 2025
13. Pei-Hsing Chen et al., “Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation” Poster 244P ELCC 2026
14. Pamart, D., et al., Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy. Clin Epigenet (2026). https://doi.org/10.1186/s13148-026-02205-x
15. Data on File, Volition
16. Canale, Annalisa et al., Evaluation of Circulating H3.1 Nucleosomes in the Plasma of Cats with Intermediate-large Cell Lymphoma, 2026, Available at SSRN: http://dx.doi.org/10.2139/ssrn.6657098
17. Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen’s Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.